Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicity

Radiotherapy and Oncology

Volumn 80, Issue 1, 2006, Pages 78-81

  Soete, Guy ^a   Arcangeli, Stefano ^b   De Meerleer, Gert ^c   Landoni, Valeria ^b   Fonteyne, Valerie ^c   Arcangeli, Giorgio ^b   De Neve, Wilfried ^c   Storme, Guy ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hypofractionation; Prostate cancer; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; UROGENITAL TRACT DISEASE;

AGED; DOSE FRACTIONATION; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL;

EID: 33746994052     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.06.005     Document Type: Article

References (38)

1. Barry M.J., Fowler Jr. F.J., O'Leary M.P., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1557
2. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
3. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
4. Brenner D.J., and Hall E.J. In response to Drs. King and Mayo: low α/β values for prostate appear to be independent of modeling details. Int J Radiat Oncol Biol Phys 47 (2000) 538-539
5. Brenner D.J., Martinez A.A., Edmundson G.K., Mitchell C., Thames H.D., and Armour E.P. Direct evidence that prostate tumours show high sensitivity to fractionation (low alpha/beta ratio), similar to late responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
6. Chappell R., Fowler J., and Ritter M. New data on the value of α/β ratio - evidence mounts that it is low. Int J Radiat Oncol Biol Phys 60 (2004) 1002-1003
7. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation therapy Oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
8. De Meerleer G., Vakaet L., Meersschout S., et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
9. Diaz A., Roach III M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
10. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after conformal radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
11. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumours really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
12. Greco C., Mazzetta C., Cattani F., et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 69 (2003) 215-222
13. Hall E.J. Time, dose and fractionation in radiotherapy. In: Hall E.J. (Ed). Radiobiology for the radiologist. 3rd ed. (1988), J.B. Lippincott Company, Philadelphia 240-259
14. Kal H.B., and Van Gellekom M.P. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 57 (2003) 1116-1121
15. Kupelian P.A., Thakkar V.V., Khuntia D., Reddy C.A., Klein E.A., and Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long term outcomes. Int J Radiat Oncol Biol Phys 63 (2005) 1463-1468
16. Livsey J.E., Cowan R.A., Wylie J.P., et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57 (2003) 1254-1259
17. Lloyd-Davies R.W., Collins C.D., and Swan A.V. Carcinoma of the prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology 36 (1990) 107-111
18. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
19. Nahum A.E., Movsas B., Horwitz E.M., Stobbbe C.C., and Chapman J.D. Incorporating clinical measurements of hypoxia into tumor local control modelling of prostate cancer: implications for the α/β ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
20. Nuyttens J.J., Milito S., Rust P.F., and Turrisi III A.T. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
21. Peeters S.T., Heemsbergen W.D., van Putten, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomised triam comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
22. Pollack A., Zagars E.K., Starkschall G., et al. Conventional vs conformal radiotherapy for prostate cancer: preliminary results of dosimetry an acute toxicity. Int J Radiat Oncol Biol Phys 34 (1996) 555-564
23. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
24. Ritter M.A., Chappell R.J., Tome W.A., and Kupelian P.A. A multi-institutional phase I/II trial of dose-per-fraction escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) s124
25. Roach III M. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 1923-1993
26. Sobin L.H., and Wittekind C. UICC (International Union Against Cancer). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
27. Soete G., Verellen D., Michielsen D., et al. Clinical use of stereoscopic X-ray positioning of patients treated with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 948-952
28. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose-escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
29. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 49 (2001) 705-712
30. Thames Jr. H.D., Withers H.R., Peters L.J., and Fletcher G.H. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8 (1982) 219-226
31. Valdagni R., Italia C., Montanaro P., et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 75 (2005) 74-82
32. Villeirs G., Van Vaerenbergh K., Vakaet L., et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 181 (2005) 424-430
33. Wachter S., Gerstner N., Goldner G., et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 59 (2001) 65-70
34. Wang J.Z., Guerrero M., and Li X.A. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
35. Yeoh E.E., Fraser R.J., McGowan R.E., et al. Evidence of efficacy without increased toxicity for hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 943-955
36. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. Am J Gastroenterol 99 (2004) 361-369
37. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
38. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239